Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1849–1872 of 16,130 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin Disorder Clear all

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: University of Central Florida; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Breast Cancer
Interventions: counseling intervention, questionnaire administration, psychosocial assessment and care, quality-of-life assessment; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2023
U.S. locations: 2
States / cities: New York, New York

Conditions: Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions: Cryosurgery, Pembrolizumab, Pheresis, Therapeutic Autologous Dendritic Cells; Procedure · Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Chronic Plaque Psoriasis
Interventions: Secukinumab 300 mg, Placebo; Drug · Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 12
States / cities: Los Angeles, California • Santa Ana, California • Rockville, Maryland + 8 more

Conditions: Melanoma (Skin)
Interventions: fenretinide, tretinoin; Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Laceration of Skin
Interventions: Ketamine, Midazolam and fentanyl; Drug
Lead sponsor: Corewell Health East; Other
Eligibility: 6 Months to 10 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Breast Neoplasm Female
Interventions: Core needle biopsy; Procedure
Lead sponsor: Rna Diagnostics Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 801 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2031
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Breast Cancer
Interventions: Proton Beam Radiotherapy; Radiation
Lead sponsor: Loma Linda University; Other
Eligibility: 40 Years to 80 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2026
U.S. locations: 2
States / cities: Loma Linda, California

Conditions: Melanoma (Skin)
Interventions: Detox-B adjuvant, recombinant interferon alfa; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1996
U.S. locations: 27
States / cities: Birmingham, Alabama • Duarte, California • La Jolla, California + 21 more

Conditions: Lupus Erythematosus, Systemic
Interventions: Cenerimod, Placebo; Drug
Lead sponsor: Viatris Innovation GmbH; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 470 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 22
States / cities: Huntington Park, California • Aurora, Colorado • Clearwater, Florida + 16 more

Conditions: Breast Cancer, Non Small Cell Lung Cancer, GastroEsophageal Cancer, Bladder Cancer
Interventions: ADCT-502; Drug
Lead sponsor: ADC Therapeutics S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 4
States / cities: Palo Alto, California • Buffalo, New York • New York, New York + 1 more

Conditions: Healthy, Sicca Syndrome, Sjögren's Syndrome
Interventions: Biopsy; Procedure
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Hartford, Connecticut • Boston, Massachusetts • Philadelphia, Pennsylvania + 1 more

Conditions: Melanoma, Liver Metastasis
Interventions: Nab-Paclitaxel (Abraxane); Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Melanoma, NSCLC, Hepatocellular Carcinoma, Urothelial Cancer, Gastric Adenocarcinoma, HNSCC, Esophageal Adenocarcinoma, Microsatellite Instability-High Solid Malignant Tumor
Interventions: Nivolumab or Pembrolizumab (dependent upon approved indication), Metformin, Rosiglitazone; Drug
Lead sponsor: Dan Zandberg; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2032
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Lupus Nephritis, Systemic Lupus Erythematosus
Interventions: KZR-616; Drug
Lead sponsor: Kezar Life Sciences, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 17
States / cities: Los Angeles, California • Upland, California • Miami, Florida + 12 more

Conditions: Lichen Planus
Interventions: INCB018424; Drug
Lead sponsor: Aaron R. Mangold; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Locally Recurrent and Metastatic Breast Cancer
Interventions: AMG 386 Placebo, AMG 386, Bevacizumab, Paclitaxel; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 228 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2014
U.S. locations: 26
States / cities: Litchfield Park, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 23 more

Conditions: Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Other Solid Tumors
Interventions: JAB-3312; Drug
Lead sponsor: Jacobio Pharmaceuticals Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 4
States / cities: Denver, Colorado • Nashville, Tennessee • Houston, Texas + 1 more

Conditions: Malignant Neoplasm of Breast Stage I
Interventions: Arm 1 600 cGY x 5 fractions, Arm 2 800 cGY x 3 fractions; Radiation
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 50 Years to 90 Years · Female only
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 4
States / cities: Los Angeles, California • New York, New York

Conditions: Triple Negative Breast Cancer, Metastatic Breast Cancer
Interventions: Gedatolisib, PTK7-ADC; Drug
Lead sponsor: Kathy Miller; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Osteoarthritis, Rheumatoid Arthritis, Post-traumatic Arthritis, Ununited Humeral Head Fracture, Irreducible 3- and 4-part Proximal Humeral Fractures, Avascular Necrosis
Interventions: Trabecular Metal Humeral Stem; Device
Lead sponsor: Zimmer Biomet; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 3
States / cities: Louisville, Kentucky • Royal Oak, Michigan • Philadelphia, Pennsylvania

Conditions: Systemic Scleroderma
Interventions: fludarabine phosphate, total-body irradiation, tacrolimus, mycophenolate mofetil, rituximab, cyclophosphamide, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation; Drug · Radiation · Biological + 1 more
Lead sponsor: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breast Cancer
Interventions: Computer Program, Focus Group, Written Materials, Questionnaires; Behavioral · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2013
U.S. locations: 2
States / cities: El Paso, Texas • Houston, Texas

Conditions: Herpes
Interventions: Versabase gel with sarracenia purpurea 20% liquid extract, placebo (versabase gel only); Other
Lead sponsor: Naturopaths International; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Flagstaff, Arizona

Search by objective public record fields.

MammoVerse: Clinicians Focus Group

Development of a Questionnaire to Evaluate Patient Expectations for Breast Reconstruction in Women With Breast Cancer or Other Conditions

Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma

Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis

Tretinoin With or Without Fenretinide in Treating Patients With Dysplastic Nevus Syndrome

IN Ketamine vs IN Midazolam and Fentanyl for Laceration Repair

RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy

Partial Breast Proton Therapy for Early Stage Breast Cancer

Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression

A Longitudinal, Observational Biomarker Study in Participants With Primary Sjogren's Syndrome

Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis

Topical Ruxolitinib Lichen Planus

Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients

A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors

Trial to Compare Radiation Fibrosis With Five Versus Three Fractions

An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer

Outcomes Study of the TM Humeral Stem Used in Primary, Total or Hemi Shoulder Arthroplasty

Low-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis

Cancer Genetics CD-ROM for Hispanics

Hsv 1 and 2 Gowey Protocol Versus Placebo